What is Nurtec Nurtec ODT?
Nurtec ODT (rimegepant) is a prescription medication used to treat and prevent migraines in adults. It is manufactured by Biohaven Pharmaceutical Holding Company Ltd and was approved by the United States Food and Drug Administration (FDA) in 2020. Nurtec ODT comes in the form of orally disintegrating tablets (ODT) that can be taken sublingually or orally.
The active ingredient in Nurtec ODT is rimegepant, which belongs to a class of drugs known as calcitonin gene-related peptide (CGRP) receptor antagonists. These drugs work by blocking the action of CGRP, a molecule responsible for causing pain and inflammation in migraines. Nurtec ODT is a fast-acting medication that can start working within 30 minutes and provide relief for up to 48 hours.
Nurtec ODT is for the treatment of acute migraine with or without aura and the preventive treatment of episodic migraine in adults. It is rapidly absorbed and has a high bioavailability, meaning that it is quickly and efficiently absorbed into the bloodstream and reaches therapeutic levels in the body.
Like all medications, Nurtec ODT has potential side effects. The most common reported side effects include nausea, indigestion, and dry mouth. However, serious side effects are rare. It is important to talk to your healthcare provider before starting any new medications to understand the potential risks and benefits.
In conclusion, Nurtec ODT is a prescription medication used to treat and prevent migraines in adults. It contains the active ingredient rimegepant, which is a CGRP receptor antagonist. Nurtec ODT is a fast-acting medication that can provide relief for up to 48 hours. It is important to talk to your healthcare provider about the potential risks and benefits of Nurtec ODT before starting treatment.
Frequently Asked Questions about nurtec nurtec odt
NURTEC ODT (orally disintegrating tablets) is for sublingual or oral use and contains 85.7 mg rimegepant sulfate, equivalent to 75 mg rimegepant free base, and the following inactive ingredients: benzyl alcohol, eucalyptol, gelatin, limonene, mannitol, menthol, menthone, menthyl acetate, sucralose, and vanillin.
NURTEC ODT is contraindicated in patients with a history of hypersensitivity reaction to rimegepant, NURTEC ODT, or any of its components. Delayed serious hypersensitivity has occurred [see Warnings and Precautions (5.1)].
Brand-name vs.
Nurtec ODT is only available as a brand-name drug. It doesn't come in a generic version. A generic drug is an exact copy of the active drug in a brand-name medication. Generics tend to cost less than brand-name drugs.
Biohaven in November recruited Pfizer to spearhead commercialization of Nurtec outside the U.S. With their forces combined, the companies aim to grow Nurtec ODT into a “massive global brand,” Biohaven CEO Vlad Coric said last year. Some 10% of people in Europe suffer from migraines, the partners said.
November 2021
Then in late November 2021, Pfizer and Biohaven linked up on a commercialization deal around Nurtec ODT and fellow CGRP candidate zavegepant outside the U.S. Together with that deal, Pfizer also made a $350 million investment in Biohaven and acquired about 3% of the latter's shares.
Nurtec ODT belongs to a class of drugs called calcitonin gene-related peptide (CGRP) receptor antagonists. CGRP receptor antagonists that are taken by mouth, such as Nurtec ODT, are also called gepants. CGRP is a protein in your brain that's thought to be involved in causing migraine symptoms.
Nurtec ODT (rimegepant) is a calcitonin gene-related peptide (CGRP) receptor blocker, which means it blocks CGRP receptors in the brain to prevent certain cellular processes that are thought to be involved with causing migraines. This can also help stop migraine pain and any inflammation (swelling) in your brain.
The most common side effects of Nurtec ODT were nausea (2.7%) and stomach pain/indigestion (2.4%). These are not the only possible side effects of Nurtec ODT. Tell your HCP if you have any side effects. You are encouraged to report adverse events related to Pfizer products by calling 1-800-438-1985 (U.S. only).
Nurtec is generally well tolerated with the most common side effects being nausea (2.7% vs. 0.8% in placebo) and stomach pain/indigestion (2.4% vs. 0.8% in placebo).
Nurtec ODT has been found to be effective for acute treatment and prevention of migraine symptoms in adults.
Receptors help cells communicate and bring about responses, such as pain. Nurtec ODT works by blocking CGRP receptors from being activated. This can help to treat and prevent migraine attacks. Nurtec ODT can also help stop the pain signals, swelling of blood vessels, and inflammation that occurs in the brain.
Nurtec - or rimegepant, as it's known chemically - is now the first drug approved in the EU for both acute and prophylactic treatment of migraines, where it will be marketed as Vydura. That's good news for Pfizer, which inked a $1.2 billion deal with Biohaven back in November to take the lead on ex-US sales.
Pfizer and Biohaven's VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine.
Biohaven Pharmaceutical Holding Company Ltd.
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) announced today the completion of its acquisition of Biohaven Pharmaceutical Holding Company Ltd., the maker of NURTEC® ODT (rimegepant), an innovative migraine therapy approved for both acute treatment and prevention of episodic migraine in adults.
About Rimegepant
Rimegepant was approved by the U.S. Food and Drug Administration (FDA) under the trade name Nurtec® ODT for the acute treatment of migraine in February 2020 and for the preventive treatment of episodic migraine in May 2021.
